Sector: Pharmaceuticals & Biotechnology - Healthcare
BSE Code: 540359
NSE Symbol: PARMAX
ISIN: INE240T01014
📋 Parmax Pharma Appoints Ms. Bhakti Aghera as Company Secretary & Compliance Officer • Ms. Bhakti Aghera (ICSI Membership No. A68683) appointed as Company Secretary and Compliance Officer • Effective date of appointment: March 25, 2026 • Appointment approved by the Board of Directors based on rec…
📉 Parmax Pharma Q3 FY2025 Results: Revenue Drops, Losses Widen • Q3 2025 revenue: ₹43.26 million (down from ₹62.84 million in Q3 2024). • Nine-month revenue: ₹87.99 million (significant decrease from ₹233.78 million last year). • Q3 2025 net loss: ₹7.32 million (vs. ₹3.95 million loss in Q3 2024)…
📅 Parmax Pharma to Review Q3 & 9M FY2025 Results on Feb 14, 2026 - Board meeting scheduled for February 14, 2026 to approve unaudited financial results for Q3 and nine months ended December 31, 2025. - Trading window for company securities closed until 48 hours after results announcement.
Parmax Pharma Q2 2025: Revenue Jumps 30% & Swings to Profit 📈 - Revenue from operations: ₹25,308.70K (Q2 2025) vs. ₹19,423.11K (previous quarter) - Total income: ₹25,378.86K (other income: ₹70.16K) - Expenses: ₹61,625.20K (materials: ₹26,780.68K, employee benefits: ₹6,504.57K) - Profit before tax…
📅 Parmax Pharma Reschedules Board Meeting to Review Financial Results - Board meeting rescheduled from Nov 14, 2024, to Nov 15, 2025. - Agenda includes approval of unaudited financial results for Q2 & H1 ending Sept 30, 2025. - Change due to unavoidable reasons. - Announcement made to BSE (Script…
📅 Parmax Pharma Board Meeting: Q2/H1 FY2025 Results on Nov 14 - Board meeting scheduled for November 14, 2025 to approve un-audited financial results for quarter/half year ended September 30, 2025. - Trading window closed until 48 hours after financial results announcement.
Parmax Pharma Appoints New Secretarial Auditor for 5-Year Term 📋 - Mr. Samsad Alam Khan appointed as Secretarial Auditor for Parmax Pharma Ltd. - Practicing Company Secretary (Membership No. F13629, CP No. 13972). - Term: Five consecutive years (FY 2025-26 to FY 2029-30). - Appointment subject to…
Parmax Pharma Q1 FY26 Results: Revenue Drops 75% 📉 - Revenue from operations fell sharply to ₹19.4M in Q1 FY26 vs ₹78.2M in Q1 FY25 - Net loss of ₹7.6M this quarter vs net profit of ₹123K same period last year - Total expenses stood at ₹27.1M, including ₹8.5M materials cost & ₹6.3M employee benef…
Parmax Pharma Appoints New Secretarial Auditor for 5-Year Term 📋 - Board meeting held on August 14, 2025 (12:15 PM – 2:35 PM IST). - Mr. Samsad Alam Khan appointed as Secretarial Auditor for FY 2025-26 to FY 2029-30 (pending shareholder approval). - Mr. Khan specializes in Company Law, SEBI regul…
Parmax Pharma Q2 2025 Results: Revenue Drops Sharply 📉 - Revenue from operations fell to ₹19,423.11 thousand in Q2 2025, down from ₹78,163.00 thousand in Q2 2024. - Net loss of ₹7,644.98 thousand, compared to a net profit of ₹123.20 thousand in the same quarter last year. - Basic EPS was negative…
Parmax Pharma Q1 FY26 Results Coming Soon 📅 - Board meeting scheduled for August 14, 2025 to approve Q1 (June 30, 2025) standalone financial results - Trading window closure in effect until 48 hours after results announcement - Company: Parmax Pharma Limited - Managing Director: Umang Gosalia
📢 Key Leadership Change at Parmax Pharma: Company Secretary Resigns • Ms. Bhakti Aghera (Membership No: A68683) has resigned as Company Secretary & Compliance Officer of Parmax Pharma Limited. • The resignation is effective from the close of business hours on June 30, 2025. • The reason for resig…
📅 Parmax Pharma Board Meeting Set for Feb 14 to Review Q3 FY24 Results • Board meeting scheduled for Friday, February 14, 2024 at 3:00 PM • Will consider and approve Un-Audited Financial Results for the quarter ended December 31, 2024 • Other matters may be discussed with the Board's permission